Trial Profile
Phase III, Placebo-Controlled, Double-Blind Crossover Study of Slow-Release Methylphenidate (Concerta) for Treatment of HIV Associated Neurocognitive Disorder
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Delirium dementia amnestic cognitive disorders
- Focus Therapeutic Use
- 19 May 2012 New trial record